Structure-based discovery of dengue virus protease inhibitors

Antiviral Research

Volumn 82, Issue 3, 2009, Pages 110-114

  Tomlinson, Suzanne M ^a   Malmstrom, Robert D ^a   Russo, Andrew ^a   Mueller, Niklaus ^b   Pang, Yuan Ping ^c   Watowich, Stanley J ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Dengue virus; Flavivirus; NS2B NS3; Protease; Small molecule inhibitor

Indexed keywords

ANTIVIRUS AGENT; ARDP 0006; ARDP 0009; INTERFERON; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR; RIBAVIRIN; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DENGUE VIRUS; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME STRUCTURE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEINASE INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DENGUE VIRUS; DESIGNER DRUGS; HUMANS; MODELS, MOLECULAR; PROTEASE INHIBITORS; SERINE ENDOPEPTIDASES; SOLUBILITY;

DENGUE VIRUS; FLAVIVIRIDAE; FLAVIVIRUS; RUMEX;

EID: 64749108083     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.02.190     Document Type: Article

References (30)

1. Alberts B., Johnson A., Lewis J., Raff M., Roberts K., and Walter P. Principles of membrane transport. Molecular Biology of the Cell. 4th ed. (2002), Garland Science, New York, New York pp. 616-619
2. Alvarez M., Rodriguez-Roche R., Bernardo L., Vasquez S., Morier L., Gonzalez D., Castro O., Kouri G., Halstead S., and Guzman M. Dengue hemorrhagic fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. Am. J. Trop. Med. Hyg. 75 (2006) 113-117
3. Bazan J., and Fletterick R. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology 171 (1989) 637-639
4. Benarroch D., Egolff M., Mulard L., Guerreiro C., Romette J., and Canard B. A structural basis for the inhibition of the NS5 dengue virus mRNA 2′-O-methyltransferase domain by ribavirin 5′-triphosphate. J. Biol. Chem. 279 (2004) 35638-35643
5. Chambers T., Weir R., Grakoui A., McCourt D., Bazan J., Fletterick R., and Rice C. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 8898-8902
6. Chanprapaph S., Saparpakorn P., Sangma C., Niyomrattanakit P., Hannongbua S., Angsuthanasombat C., and Katzenmeier G. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem. Biophys. Res. Commun. 330 (2005) 1237-1246
7. Erbel P., Schiering N., D'Arcy A., Renatus M., Kroemer M., Lim S., Yin Z., Keller T., Vasudevan S., and Hommel U. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat. Struct. Mol. Biol. 13 (2006) 372-373
8. Falgout B., Pethel M., Zhang Y., and Lai C. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J. Virol. 65 (1991) 2467-2475
9. Gubler D., Juno G., and Markoff L. Flaviviruses. In: Fields B., Knipe D., Howley P., Chanock R., Melnick J., Monath T., Roizman B., and Strauss S. (Eds). Field's Virology, vol. 1. 3rd ed. (1996), Lippincott William & Wilkins, Philadelphia, PA 961-1034
10. Ganesh V.K., Muller N., Judge K., Luan C.-H., Padmanabhan R., and Murthy K.H.M. Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Bioorg. Med. Chem. 13 (2005) 257-264
11. Gerlier D., and Thomasset N. Use of MTT colorimetric assay to measure cell activation. J. Immunol. Methods 94 (1986) 57-63
12. Ghose A., and Viswanadhan V. Fast continuum electrostatics methods for structure-based ligand design. Combinatorial Library Design and Evaluation: Principles, Software, Tools, and Applications in Drug Discovery (2001), CRC Press, New York, New York p. 223
13. Guex N., and Peitsch M.C. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18 (1997) 2714-2723
14. Halstead S. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60 (2003) 421-467
15. Halstead S.B., and Simasthien P. Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biological properties of dengue viruses and their association with disease response in the host. Yale J. Biol. Med. 42 (1970) 276-292
16. Laird E., and Blake J. Structure-based generation of viable leads from small combinatorial libraries. Curr. Opin. Drug Discov. Dev. 7 (2004) 354-359
17. Leung D., Schroder K., White H., Fang N., Stoermer M., Abbenante G., Martin J., Young P., and Fairlie D. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J. Biol. Chem. 276 (2001) 45762-45771
18. Leyssen P., De Clercq E., and Neyts J. Perspectives for the treatment of infections with Flaviviridae. Clin. Microbiol. Rev. 13 (2000) 67-82
19. Morens D., and Fauci A. Dengue and hemorrhagic fever: a potential threat to public health in the United States. JAMA 299 (2008) 214-216
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
21. Murthy K., Clum S., and Padmanabhan R. Crystal structure and insights into interaction of the active site with substrates by molecular modeling and structural analysis of mutational effects. J. Biol. Chem. 274 (1999) 5573-5580
22. Murthy K., Judge K., DeLucas L., and Padmanabhan R. Crystal structure of dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design. J. Mol. Biol. 301 (2000) 759-767
23. Pang Y.-P., Perola E., Xu K., and Prendergast F. EUDOC: a computer program for identification of drug interaction sites in macromolecules and drug leads from chemical databases. J. Comput. Chem. 22 (2001) 1750-1771
24. Pang Y.-P., et al. EUDOC on Blue Gene: accelerating the transfer of drug discoveries from laboratory to patient. IBM J. Res. Dev. 52 (2008) 69-81
25. Sabin A. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1 (1952) 30-50
26. Sampath A., and Padmanabhan R. Molecular targets for flavivirus drug discovery. Antivir. Res. 81 (2009) 6-15
27. Wang Q., and Pang Y.-P. Accurate reproduction of 161 small-molecule complex crystal structures using the EUDOC program: expanding the use of EUDOC to supramolecular chemistry. PLoS ONE 2 (2007) e531
28. Yin Z., Patel S.J., Wang W.-L., Wang G., Chan W.-L., Rao K.R.R., Alam J., Jeyaraj D.A., Ngew X., Patel V., Beer D., Lim S.P., Vasudevan S.G., and Keller T.H. Peptide inhibitors of dengue virus NS3 protease. Part 1. Warhead. Bioorg. Med. Chem. Lett. 16 (2006) 36-39
29. Yin Z., Patel S.J., Wang W.-L., Chan W.-L., Rao K.R.R., Wang G., Ngew X., Patel V., Beer D., Knox J.E., Ma N.L., Ehrhardt C., Lim S.P., Vasudevan S.G., and Keller T.H. Peptide inhibitors of dengue virus NS3 protease. Part 2. SAR study of tetrapeptide aldehyde inhibitors. Bioorg. Med. Chem. Lett. 16 (2006) 40-43
30. Yusof R., Clum S., Wetzel M., Murthy K., and Padmanabhan R. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J. Biol. Chem. 275 (2000) 9963-9969